In the first week following its April 18 approval, Pharmacia finds "a great number of hospital orders [for Zyvox] coming directly to us and bypassing the wholesalers," Exec VP and Head of Global Business Management Carrie Cox said during an April 25 teleconference (1"The Pink Sheet" April 24, p. 4). Pricing for Zyvox I.V. therapy has been set at $115/day, which Pharmacia said is less than half the cost of daily therapy with Aventis' injectable streptogramin antibiotic Synercid (quinupristin/dalfopristin). Zyvox oral therapy will cost $85/day
You may also be interested in...
Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials